Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus SBRT versus SBRT alone in oligometastatic soft tissue sarcoma
2024-511313-38-00Phase 2Authorised
- Sponsor
- Centre Antoine Lacassagne
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in soft tissue sarcoma (STS) (2 arms), sponsored by Centre Antoine Lacassagne. Primary endpoint: Progression-free survival rate at 6 months. Planned start Nov 2024; status: authorised.
02
Drugs
atezolizumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2024-511313-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511313-38-00.